Jihye Yang
About Jihye Yang
Jihye Yang is the General Manager at BeiGene Korea, with extensive experience in oncology marketing and market access roles.
Title at BeiGene
Jihye Yang is currently the General Manager at BeiGene Korea. She took on this role in May 2022. Her position involves overseeing the company's operations and strategy in Korea, leveraging her extensive experience in the oncology sector to support BeiGene's mission to improve oncology treatments.
Professional Experience at Novartis
Before joining BeiGene, Jihye Yang worked at Novartis as the Head of Oncology Solid Business Franchise from 2021 to 2022. In this role, she was responsible for managing and driving the business strategy and execution for the oncology solid tumors division, ensuring the alignment of business operations with the company's overall goals.
Roles at 화이자
At 화이자, Jihye Yang held several significant roles focused on oncology and market access. She served as the Market Access Lead (Secondment) for six months in 2020, focusing on the South Korean market. Prior to that, she was the Oncology Marketing Lead from 2018 to 2020, a role she transitioned into after serving as the Oncology Marketing Manager from 2017 to 2018. These positions involved the development and execution of marketing strategies to enhance the company's oncology offerings.
Educational Background
Jihye Yang holds a Bachelor of Science in Biology from Yonsei University. Her educational background laid a solid foundation for her career in the pharmaceutical and biotechnology industries, equipping her with the necessary knowledge and skills to excel in her various roles in oncology marketing and management.
Expertise in Oncology and Market Access
Jihye Yang has built an extensive career in oncology marketing and market access. Her roles at 화이자, Novartis, and now BeiGene, have involved strategic planning, market analysis, and the execution of business strategies tailored to the oncology sector. Her expertise includes driving market access initiatives and developing marketing strategies to support innovative oncology treatments.